Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 4,035
Out of 4,996 analysts
88
Total ratings
29.73%
Success rate
-19.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Market Perform | $21 → $3 | $4.13 | -27.36% | 10 | Jul 22, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $31.62 | +137.19% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $29.07 | -7.12% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $34.02 | +117.52% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $16.24 | -32.27% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.89 | +295.66% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.55 | +1,045.04% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.40 | +576.13% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $43.92 | -31.69% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.73 | +593.64% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $7.57 | +4,523.51% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $7.70 | +237.66% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.15 | +1,940.82% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $9.05 | +209.39% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $11.57 | +358.08% | 7 | Aug 5, 2021 |
Replimune Group
Jul 22, 2025
Downgrades: Market Perform
Price Target: $21 → $3
Current: $4.13
Upside: -27.36%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $31.62
Upside: +137.19%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $29.07
Upside: -7.12%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $34.02
Upside: +117.52%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $16.24
Upside: -32.27%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.89
Upside: +295.66%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.55
Upside: +1,045.04%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.40
Upside: +576.13%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $43.92
Upside: -31.69%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.73
Upside: +593.64%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $7.57
Upside: +4,523.51%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $7.70
Upside: +237.66%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.15
Upside: +1,940.82%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $9.05
Upside: +209.39%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $11.57
Upside: +358.08%